BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer. Rome Therapeutics Inc. launched...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

As vaccine and therapeutic companies ramp up clinical trials for COVID-19, other biotechs are halting trials to protect patients and to preserve hospital resources. The ripple effects of the pandemic are also beginning to play...
BioCentury | Mar 12, 2019
Clinical News

GeNeuro finds path forward for temelimab in non-active progressive MS

Two-year data from GeNeuro’s Phase IIb ANGEL-MS extension trial to treat relapsing-remitting multiple sclerosis has shown temelimab produced a sustained neuroprotective effect and provided an early signal for clinical benefit. The results support a move...
BioCentury | Sep 21, 2018
Company News

Servier declines rights to GeNeuro's GNbAC1

Servier (Neuilly-sur-Seine, France) declined to exercise an option to license rights outside the U.S. and Japan from GeNeuro S.A. (Euronext:GNRO) to develop and commercialize GNbAC1 to treat multiple sclerosis. The companies said Servier's decision was...
BioCentury | Mar 30, 2018
Clinical News

GeNeuro reports 12-month Phase IIb data for RRMS candidate

GeNeuro S.A. (Euronext:GNRO) and Servier (Suresnes, France) reported 12-month data from the double-blind, European Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis (RRMS). Patients received placebo or one of three doses of...
BioCentury | Sep 22, 2017
Clinical News

GeNeuro's GNbAC1 misses in Phase IIb for RRMS

GeNeuro S.A. (Euronext:GNRO) and Servier (Neuilly-sur-Seine, France) reported data from the 12-month Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis (RRMS) showing that once-monthly IV GNbAC1 missed the primary endpoint of reducing...
BioCentury | Jun 2, 2017
Clinical News

GeNeuro starts Phase IIa of GNbAC1 in Type I diabetes

In April, GeNeuro S.A. (Euronext:GNRO) began a Phase IIa trial to evaluate GNbAC1 in about 60 recently diagnosed adults with Type I diabetes. The placebo-controlled, Australian trial will evaluate safety as the primary endpoint. Secondary...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BioCentury | Apr 19, 2016
Financial News

GeNeuro raises EUR 33 million in IPO

GeNeuro S.A. (Euronext:GNRO) raised EUR 33 million ($37.3 million) through the sale of 2.5 million shares at EUR 13 in an IPO. Trading of its shares is expected to begin Tuesday on Euronext. GeNeuro's GNbAC1...
BioCentury | Jan 11, 2016
Clinical News

GNbAC1: Phase IIb started

GeNeuro began the placebo-controlled, European Phase IIb CHANGE-MS trial to evaluate GNbAC1 in 260 patients. In 2014, GeNeuro granted Servier (Neuilly-sur-Seine, France) an option to license exclusive rights to develop and commercialize GNbAC1 worldwide, excluding...
Items per page:
1 - 10 of 12